ReviewBritish journal of cancer2020

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).

Priyanka Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.